Clinical

Dataset Information

0

Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

ABSTRACT: The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel, Sutent, and/or Inlyta therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use

DISEASE(S): Gastrointestinal Stroma Tumors,Carcinoma,Carcinoma, Renal Cell, Advanced,Carcinoma, Renal Cell,Lymphoma, Mantle-cell,Lymphoma,Gastrointestinal Stromal Tumors

PROVIDER: 2057080 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
| S-EPMC6716603 | biostudies-literature
Unknown Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
| S-EPMC8798318 | biostudies-literature
Unknown Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
| S-EPMC7060483 | biostudies-literature
Unknown Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.
| S-EPMC3956829 | biostudies-literature
Unknown A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma.
| S-EPMC7225300 | biostudies-literature
Unknown Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
| S-EPMC8493486 | biostudies-literature
Unknown Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
| S-EPMC6801695 | biostudies-literature
Unknown Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.
| S-EPMC6558845 | biostudies-literature
Unknown Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
| S-EPMC7471136 | biostudies-literature
Unknown Axitinib in Metastatic Renal Cell Carcinoma.
| S-EPMC3873008 | biostudies-other